Physician profile
Alan Lim
NPI 1104896935
$5,544.73
in general payments reported to CMS, 2019-2025
30 companies · $818 in 2025
The $818 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,012 · 2020: $324 · 2021: $50.00 · 2022: $329 · 2023: $734 · 2024: $1,278 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $871.14 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $634.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $441.26 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $377.32 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $376.02 | 2019-2025 | Capvaxive, Belsomra, Gardasil 9 |
| Pfizer INC. | $350.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.04 | 2019-2025 | Jardiance |
| Abbott Laboratories | $270.95 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $235.73 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $224.47 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $178.92 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Amgen INC. | $178.40 | 2019-2020 | |
| Abbvie INC. | $164.75 | 2019-2025 | |
| Vivus LLC | $139.92 | 2019-2024 | Qsymia |
| Astellas Pharma US INC | $139.55 | 2022-2025 | Veozah, Myrbetriq, Xtandi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $134.80 | 2019-2024 | |
| Sanofi Pasteur INC. | $79.31 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.69 | 2024 | |
| Allergan, INC. | $55.55 | 2019-2020 | |
| Exact Sciences Corporation | $53.83 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $42.71 | 2019-2020 | |
| Amarin Pharma, INC. | $37.63 | 2019-2020 | |
| Medtronic, INC. | $33.46 | 2022-2025 | Inceptiv |
| Endo Pharmaceuticals INC. | $31.58 | 2020 | |
| Hologic Sales and Service, LLC | $25.56 | 2019 | |
| Ibsa Pharma INC. | $16.88 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2019 | |
| Currax Pharmaceuticals LLC | $14.70 | 2019 | |
| Springworks Therapeutics, INC. | $14.57 | 2024 | Ogsiveo |
| Upsher-Smith Laboratories LLC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.